Press releases

Non Regulatory

December 7, 2015

Oasmia Pharmaceutical’s Next Generation Anti-cancer Drug Docecal Approved for Clinical Trials

Non Regulatory

December 3, 2015

Interim report for the period May – October 2015

Regulatory

November 30, 2015

Publication of change in the total number of shares and votes in Oasmia

Non Regulatory

November 20, 2015

Oasmia Pharmaceutical’s Lead Human Cancer Drug Paclical® Generates Strong Interest at the 19th Annual Russian Cancer Congress

Non Regulatory

November 5, 2015

Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®

Non Regulatory

November 5, 2015

Oasmia Pharmaceutical AB Announces an Additional and Partial Exercise of Over-Allotment

Non Regulatory

October 30, 2015

Oasmia Pharmaceutical receives order of $7.5 million in end-user value for the Russian market

Non Regulatory

October 29, 2015

Oasmia Pharmaceutical AB Announces Closing of U.S. Initial Public Offering of American Depositary Shares and Warrants and NASDAQ Listing

Non Regulatory

October 28, 2015

Oasmia Pharmaceutical AB Executes First Commercial Order of Paclical for the Russian market

Regulatory

October 23, 2015

Nexttobe extends loan to Oasmia

Non Regulatory

October 23, 2015

Oasmia Pharmaceutical AB Announces Pricing of Public Offering of American Depositary Shares and NASDAQ Listing

Non Regulatory

October 20, 2015

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering

Non Regulatory

October 5, 2015

Oasmia Pharmaceutical AB Announces Commercial Launch of Paclical in Russia and CIS Countries

Non Regulatory

September 30, 2015

Communiqué from Oasmia’s Annual General Meeting 2015

Non Regulatory

September 28, 2015

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Adds Warrants

Regulatory

September 5, 2015

Interim report for the period May – July 2014

Non Regulatory

September 3, 2015

Interim report for the period May – July 2015

Regulatory

August 31, 2015

Notice convening the Annual General Meeting of Oasmia Pharmaceutical AB

Non Regulatory

August 21, 2015

The Oasmia Pharmaceutiacal Annual Report is now published

Non Regulatory

August 17, 2015

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Announces Investor Roadshow

Non Regulatory

August 4, 2015

Oasmia Pharmaceutical Announces Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®

Non Regulatory

August 3, 2015

Oasmia Pharmaceutical Extends Form F-1/A Registration Statement to Include New Key Material Data and Final Full-Year Financials

Non Regulatory

July 7, 2015

Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing

Non Regulatory

July 7, 2015

Oasmia Pharmaceutical Launches US Brand and Sales Platform

Non Regulatory

July 4, 2015

Year-end report for the fiscal year May 2014 – April 2015

Non Regulatory

May 29, 2015

Changes in Oasmia’s Board of Directors and Management

Regulatory

May 29, 2015

Communiqué from Oasmia’s Extraordinary General Meeting 2015

Non Regulatory

May 7, 2015

Oasmia gives notice of Extraordinary General Meeting

Regulatory

May 7, 2015

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB (publ)

Non Regulatory

April 24, 2015

Results from Oasmia’s Phase III study will be presented at ASCO

Regulatory

April 20, 2015

Oasmia’s lead cancer product Paclical® receives market approval in the Russian Federation

Non Regulatory

March 5, 2015

Interim report for the period May 2014 – January 2015

Non Regulatory

February 17, 2015

Oasmia initiates clinical Phase II study with Doxophos Vet for the treatment of canine lymphoma